rs104894011 — GCK Glu265Lys (MODY2)

Pathogenic glucokinase missense variant causing MODY2 — mild, stable fasting hyperglycemia that typically requires no pharmacologic treatment

See your personal result for GCK

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

GCK Glu265Lys — The Pancreatic Glucose Sensor, Set Too High

Glucokinase (GCK) is the enzyme that tells your pancreatic beta cells how much glucose is in the bloodstream. Think of it as a thermostat: it sets the glucose threshold at which insulin secretion begins. Normally, beta cells start releasing insulin when blood glucose rises above about 5.0 mmol/L (90 mg/dL). When glucokinase carries a pathogenic variant like Glu265Lys, that thermostat is set approximately 1–3 mmol/L too high — beta cells remain "unaware" of the glucose until it reaches a higher level than normal, producing mild, lifelong fasting hyperglycemia.

This is MODY2 (Maturity-Onset Diabetes of the Young, type 2), the most common form of monogenic diabetes11 monogenic diabetes
Monogenic diabetes arises from a single-gene defect, as opposed to type 1 or type 2 diabetes which involve many genes and environmental factors. MODY accounts for 1–5% of all diabetes diagnoses but is frequently misdiagnosed as type 1 or type 2.. The Glu265Lys variant substitutes a negatively charged glutamic acid at position 265 of the glucokinase protein with a positively charged lysine residue, destabilizing the protein structure and reducing its functional activity.

The Mechanism

Glucokinase (hexokinase IV) phosphorylates glucose to glucose-6-phosphate, the first step in glycolysis. In beta cells, this reaction couples extracellular glucose concentration directly to insulin secretion. Unlike other hexokinases, glucokinase has a sigmoidal kinetic response to glucose and is not inhibited by its product — properties that make it exquisitely suited as a glucose sensor.

The Glu265Lys substitution22 Glu265Lys substitution
The glutamic acid at codon 265 is located in a structural region of glucokinase (exon 7). Biochemical studies show the mutation primarily destabilizes the protein's tertiary structure — it reduces thermal stability and total functional protein — rather than directly abolishing the active site. shifts the glucose-sensing threshold upward. Beta cells respond to glucose, but they don't begin secreting insulin until blood glucose climbs 1–3 mmol/L higher than normal. This produces fasting glucose values consistently in the range of 5.5–8.0 mmol/L (99–144 mg/dL), with HbA1c typically between 5.6–7.6%.

Crucially, the defect is in the sensor, not in overall beta-cell capacity or insulin action. Insulin secretion is normal once the higher threshold is crossed, and insulin sensitivity is preserved. This is why GCK-MODY behaves so differently from type 1 or type 2 diabetes: there is no progressive beta-cell failure, no insulin resistance, and the hyperglycemia is stable over decades.

The Evidence

Galán et al. (2006)33 Galán et al. (2006)
Effects of novel MODY-associated mutations on glucokinase activity and protein stability. Biochemical Journal, 2006. directly characterized the Glu265Lys mutation, finding that it "strongly affects protein stability, suggesting a possible structural defect" rather than a kinetic impairment, distinguishing it mechanistically from mutations that abolish enzymatic catalysis.

Estalella et al. (2008)44 Estalella et al. (2008)
Biochemical characterization of novel glucokinase mutations isolated from Spanish MODY2 patients. J Human Genetics, 2008. confirmed E265K produces reduced enzymatic activity alongside five other Spanish MODY2 mutations.

Large registry studies establish the clinical picture. A Spanish cohort Estalella et al. (2007)55 Estalella et al. (2007)
Mutations in GCK and HNF-1alpha explain the majority of MODY cases in Spain. Clinical Endocrinology, 2007. of 95 families found GCK mutations explained 80% of MODY, with affected individuals managed predominantly by diet alone — in sharp contrast to HNF1A-MODY, which requires sulfonylureas or insulin in most cases.

The Brazilian MODY Registry (2017)66 Brazilian MODY Registry (2017)
Giuffrida et al., Diabetes Research and Clinical Practice, 2017 — 311 patients across multiple subtypes. found only 5% of GCK-MODY patients required sulfonylureas and only 5% required insulin — versus 83% and 17% respectively for HNF1A-MODY. Discontinuing pharmacologic therapy in GCK-MODY does not alter HbA1c, confirming the hyperglycemia is a fixed set-point, not progressive dysregulation.

The NIH GeneReviews entry for GCK-MODY77 NIH GeneReviews entry for GCK-MODY
Chakera et al., updated regularly. GeneReviews — Glucokinase MODY. NCBI Bookshelf NBK500456. summarizes the diagnostic criteria: fasting glucose 5.5–8.0 mmol/L, HbA1c 5.6–7.3% (age ≤40) or 5.9–7.6% (age >40), present from birth, and not progressive.

Practical Actions

The most important clinical insight for GCK-MODY carriers is that their elevated fasting glucose is a stable set-point, not a disease requiring treatment. Sulfonylureas stimulate insulin secretion below the elevated threshold, producing hypoglycemia without benefit. Insulin provides no sustained glycemic improvement because the beta cells will simply re-establish the same raised threshold. Multiple studies confirm that stopping pharmacologic treatment in previously misdiagnosed GCK-MODY patients does not change HbA1c.

The correct response is accurate diagnosis, family cascade testing (50% of children will inherit the variant), and — in pregnant carriers — specific obstetric management based on fetal genotype.

Pregnancy deserves special attention. If the fetus inherits the GCK variant, its own beta cells will also have the raised threshold, meaning normal fetal insulin production occurs and birth weight is unaffected. If the fetus does NOT inherit the variant, it has normal glucokinase — normal fetal beta cells will produce extra insulin in response to the mildly elevated maternal glucose, promoting excessive fetal growth (macrosomia). In this scenario, maternal insulin therapy during pregnancy can normalize fetal growth; fetal abdominal circumference on ultrasound is used to infer the fetal genotype and guide treatment decisions.

Interactions

GCK-MODY does not interact with the common polygenic type 2 diabetes risk variants in a clinically meaningful way — the mechanism is entirely different (sensor threshold vs progressive beta-cell failure). Carriers of GCK Glu265Lys should inform family members, as the autosomal dominant inheritance pattern means each first-degree relative has a 50% chance of carrying the same variant.

Other GCK coding variants (hundreds have been described) cause the same MODY2 phenotype through distinct mechanisms. Related pathogenic GCK variants tracked in databases include other exon 7 missense mutations. The GCK activation mutations causing congenital hyperinsulinism (the opposite phenotype — hypoglycemia) are entirely distinct.

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal glucokinase Normal

Normal GCK sequence — standard glucose-sensing threshold

You carry two copies of the normal GCK allele. Your glucokinase enzyme sets the pancreatic glucose-sensing threshold at the normal level (~5.0 mmol/L), and your fasting blood glucose is expected to be within the standard reference range. More than 99.99% of people globally share this genotype. You are not at risk for MODY2 from this variant.

CT MODY2 Carrier High Risk

Carries one copy of Glu265Lys — MODY2 (glucokinase diabetes)

The Glu265Lys substitution destabilizes the glucokinase protein structure (NM_000162.5: c.793G>A, detected as C>T on the plus strand at chr7:44147720). Heterozygous carriers function with one normal and one defective glucokinase allele. Because glucokinase in beta cells acts as a glucose threshold sensor, even partial reduction in functional enzyme shifts the insulin-secretion set point upward. The result is not random dysregulation — it is a precisely calibrated, permanent upward shift in fasting glucose.

Key distinguishing features from type 2 diabetes: - Fasting hyperglycemia present at birth (not acquired) - Glucose elevation stable over decades — no progressive deterioration - Postprandial glucose rise is normal or only mildly elevated - Insulin sensitivity is normal - No obese/metabolic syndrome phenotype required - HbA1c typically does not exceed 7.6% without other metabolic stressors - Microvascular complications (retinopathy, nephropathy) are rare

Treatment studies confirm that discontinuing oral hypoglycemics or insulin in GCK-MODY patients does not raise HbA1c — the condition is pharmacologically unresponsive because the underlying mechanism bypasses the normal insulin- secretion stimulus.

Pregnancy: If the fetus inherits the GCK variant, fetal insulin production is also shifted upward in threshold — birth weight is normal. If the fetus does NOT inherit the variant, the fetus responds to the slightly elevated maternal glucose with excessive insulin secretion, producing macrosomia. Fetal abdominal circumference measurements (ultrasound at 28–32 weeks) allow inference of fetal genotype and guide the decision about maternal insulin therapy.

TT Homozygous MODY2 Homozygous

Carries two copies of Glu265Lys — homozygous GCK-MODY, more severe hyperglycemia

Homozygous GCK-MODY arises when both parental chromosomes carry pathogenic GCK variants. In the case of Glu265Lys homozygosity, both alleles produce a structurally destabilized glucokinase. The consequence is a more severe upward shift in the insulin-secretion threshold compared to heterozygotes.

Published case reports and the functional literature suggest homozygous loss of both glucokinase alleles produces neonatal or permanent neonatal diabetes (PNDM) in some families. The phenotype at homozygosity depends on the specific mutation: some retain partial activity (as Glu265Lys may), which may moderate the clinical severity relative to complete loss-of-function homozygosity.

Given the extreme rarity, a formal assessment at a center with monogenic diabetes expertise is essential to characterize the clinical phenotype, determine whether pharmacologic intervention is warranted, and guide family management.